The Larvol Group, a Software as a Service (SaaS) company with 125 employees, announced the launch of Veri, their new decision support and competitive intelligence tool during the 2020 ASCO Annual Meeting. The Veri platform offers access to a knowledgebase for predictive biomarkers in oncology and is free for non-commercial use.
SAN FRANCISCO–(BUSINESS WIRE)–The Larvol Group, a Software as a Service (SaaS) company with 125 employees, announced the launch of Veri, their new decision support and competitive intelligence tool during the 2020 ASCO Annual Meeting. The Veri platform offers access to a knowledgebase for predictive biomarkers in oncology and is free for non-commercial use.
“Veri is an extremely ambitious project and our focus is to move beyond the capabilities of existing knowledgebases by providing biomarker data that is relevant, up to date, and reviewed by a trusted team of experts. We’ve perfected pharma and biotech data curation for over 15 years, and we’re now carrying that forward in the biomarker space,” said Bruno Larvol, Founder & CEO.
Veri enables users to search for biomarkers and view associated drug responses, ordered by level of evidence (FDA approval to case studies). Users can also access biomarker related heatmaps, trials, and news. In addition, users receive tailored biomarker and companion diagnostic alerts. Co-developed in partnership with major US pharmaceutical companies, features include:
Larvol provides SaaS solutions to support the needs of the pharmaceutical and biotech industry. Their products include secondary competitive intelligence, KOL tracking, and conference planning solutions. Larvol curates data using a proven combination of broad therapeutic-area expertise and proprietary natural language processing technology to keep their customers at the forefront of the industry. The 100% remote Larvol team includes MDs, PhDs, and industry professionals who curate data from over 25,000 sources and distill the most relevant information into concise reports that provide real-time insights and time-saving analysis.
For more information about Larvol Veri or sales inquiries, please contact us at firstname.lastname@example.org.
Sabrina Bellisario – email@example.com
The advent of precision oncology is marked by many new changes and improvements in diagnostic, prognostic and treatment methods for cancer patients. Researchers looking to bring new drugs to market are now also privy to a vast database of material from previously conducted studies thanks to a push forward in research collaborations and the creation of shared data hubs.